Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous CD34+ hematopoietic stem cells
- Development stage
- Phase 3
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous CD34+ hematopoietic stem cells are progenitor cells harvested from a patient's own peripheral blood, typically following mobilization with agents like G-CSF or plerixafor. These cells are used in the context of autologous stem cell transplantation (ASCT) to reconstitute the bone marrow and immune system after a patient has received myeloablative high-dose chemotherapy, such as the BEAM regimen. In clinical research led by Memorial Sloan Kettering Cancer Center specifically for diffuse large B-cell lymphoma (DLBCL), investigators are studying the impact of the CD34+ cell dose on patient outcomes. The research evaluates whether a higher dose (6-8 x 10^6 cells/kg) compared to a standard dose (3-4 x 10^6 cells/kg) leads to faster recovery of the absolute lymphocyte count (ALC), which is associated with improved progression-free survival in relapsed or refractory DLBCL patients.
- Other names
- CD34+ stem cellsautologous peripheral blood stem cellsPBSCCD34+ cells
Beyond the preview
Go deeper on autologous CD34+ hematopoietic stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous CD34+ hematopoietic stem cells.